Blueprint
PROSPECTUS
|
Filed
Pursuant to Rule 424(b)(3)
Registration
No. 333-223452
|
Up to 2,927,658
Shares of Common Stock
This prospectus
relates to the resale of up to 2,927,658 shares (the
“Shares”) of our common stock, par value $.001 per
share of Cellular Biomedicine Group, Inc. a Delaware corporation,
for sale by the selling stockholders named herein (the
“Selling Stockholders”) for their own accounts. The
shares to be sold by the Selling Stockholders include: (i) up to
41,667 shares of our common stock issued in connection with a $0.5
million closing on a private placement financing on December 22,
2017 (the “Management Tranche”), (ii) up to 1,166,667
shares of our common stock issued in connection with a $14.0
million closing on a private placement financing on December 28,
2017 (the “Investor Tranche”), and (iii) up to
1,719,324 shares of our common stock issued in connection with a
$30.6 million closing on a private placement financing on February
5, 2018 (the “February PIPE”).
To the extent the
Selling Stockholders wish to sell their shares of our common stock
as provided for herein, they may offer and sell such shares on a
continuous or delayed basis in the future. These sales may be
conducted in the open market or in privately negotiated
transactions and at market prices, fixed prices or negotiated
prices. We will not receive any of the proceeds from the sale of
the Shares. See “Use of Proceeds” on page 19. We have
agreed to pay the expenses in connection with the registration of
the Shares.
Our common stock is
listed on The NASDAQ Global Market under the symbol
“CBMG.” The last reported sale price of our common
stock on April 10, 2018 was $20.25.
Investing
in our securities involves a high degree of risk. You should review
carefully the risks and uncertainties described under the heading
“Risk Factors” beginning on page 18, and under similar
headings in the other documents that are incorporated by reference
into this prospectus or any prospectus supplement before making a
decision to purchase our securities.
Neither
the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
The
date of this prospectus is April 11, 2018.
TABLE
OF CONTENTS
|
Page
|
Cautionary Note
Regarding Forward-Looking Statements
|
ii
|
Prospectus
Summary
|
1
|
The
Offering
|
17
|
Risk
Factors
|
18
|
Use of
Proceeds
|
19
|
Determination of
Offering Price
|
19
|
Selling
Stockholders
|
20
|
Plan of
Distribution
|
21
|
Description of
Securities to be Registered
|
23
|
Legal
Matters
|
24
|
Experts
|
24
|
Where You Can Find
Additional Information
|
24
|
Incorporation of
Documents by Reference
|
25
|
Disclosure of
Commission Position of Indemnification For Securities Law
Violations
|
26
|
You
should rely only on the information we have provided or
incorporated by reference in this prospectus or in any prospectus
supplement. We have not authorized anyone to provide you with
information different from that contained or incorporated by
reference in this prospectus or in any prospectus
supplement.
You
should assume that the information contained in this prospectus and
in any prospectus supplement is accurate only as of their
respective dates and that any information we have incorporated by
reference is accurate only as of the date of the document
incorporated by reference, regardless of the time of delivery of
this prospectus or any prospective supplement or any sale of
securities.
In
this prospectus, we rely on and refer to information and statistics
regarding our industry. We obtained this statistical, market and
other industry data and forecasts from publicly available
information. While we believe that the statistical data, market
data and other industry data and forecasts are reliable, we have
not independently verified the data.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and
any accompanying prospectus supplement and the documents we have
filed or will file with the SEC that are or will be incorporated by
reference into this prospectus and the accompanying prospectus
supplement contain forward-looking statements, within the meaning
of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
that involve risks and uncertainties. Any statements contained, or
incorporated by reference, in this prospectus and any accompanying
prospectus that are not statements of historical fact may be
forward-looking statements. When we use the words
“anticipate,” “believe,”
“could,” “estimate,” “expect,”
“intend,” “may,” “plan,”
“predict,” “project,” “will”
and other similar terms and phrases, including references to
assumptions, we are identifying forward-looking statements.
Forward-looking statements involve risks and uncertainties which
may cause our actual results, performance or achievements to be
materially different from those expressed or implied by
forward-looking statements.
A variety of
factors, some of which are outside our control, may cause our
operating results to fluctuate significantly. They
include:
●
our
plans and expectations regarding the timing and outcome of our
research, development, manufacturing, distribution and
commercialization efforts, whether with partners or on our own,
with primary research and manufacturing facilities in China,
relating to our therapies derived from two major cell platforms:
(i) Immune Cell therapy for treatment of a broad range of cancers
using vaccine, T Central Memory (“Tcm”) Cell, T Cells
Receptor (“TCR”) clonality, Chimeric Antigen Receptor T
cell (“CAR-T”) and anti-PD-1 technologies for various
liquid and solid cancerous diseases, and (ii) human adipose-derived
mesenchymal progenitor cells (“haMPC”) for treatment of
joint and autoimmune diseases comprised of Knee Osteoarthritis
(“KOA”), and Cartilage Defect (“CD”)
Asthma, and Chronic Obstructive Pulmonary Disease ("COPD")
autologous and allogeneic therapies and any other proposed
products, product candidates or approved products;
●
the
domestic and international regulatory process and related laws,
rules and regulations governing our technologies and our approved
and proposed products and formulations, including: (i) the timing,
status and results of our or our commercial partners’ filings
with the U.S. Food and Drug Administration (“FDA”),
Ministry of Health (“MOH”) and the China Food and Drug
Administration (“CFDA”) or their f equivalents in other
jurisdictions, (ii) the timing, status and results of non-clinical
work and clinical studies, including regulatory review thereof and
(ii) the heavily regulated industry in which we operate our
business generally;
●
the
significant challenges our newly acquired technology platform
presents;
●
our
ability to enter into strategic partnerships for the development,
commercialization, manufacturing and distribution of our products
and product candidates;
●
Our
reliance in significant part on outside scientists and their
third-party research institutions for research and development and
early clinical testing of our product candidates;
●
our
ability, or the ability of our commercial partners to actually
develop, commercialize, manufacture or distribute our products and
product candidates;
●
our
ability to generate commercially viable products and the market
acceptance of our cell therapy and cell banking technologies and
our proposed products and product candidates;
●
our
ability to finance our operations on acceptable terms, either
through the raising of capital, the incurrence of convertible or
other indebtedness or through strategic financing or
commercialization partnerships;
●
the
protection and control afforded by our patents or other
intellectual property, and any interest patents or other
intellectual property that we license, or our or our
partners’ ability to enforce our rights under such owned or
licensed patents or other intellectual property;
●
our
ability to maintain our licenses, patents or other intellectual
property;
●
the
outcome of ongoing or potential future litigation or other claims
or disputes relating to our business, technologies, products or
processes;
●
the
ability of our manufacturing partners to supply us or our
commercial partners with clinical or commercial supplies of our
products in a safe, timely and regulatory compliant manner and the
ability of such partners to address any regulatory issues that have
arisen or may in the future arise;
●
competition
existing today or that will likely arise in the future;
and
●
regulatory
oversight of our company by the Securities and Exchange Commission
(“SEC”), FDA, CFDA, the NASDAQ Stock Market and other
regulatory agencies.
The foregoing does
not represent an exhaustive list of risks that may impact upon the
forward-looking statements used herein or in the documents
incorporated by reference herein. Please see “Risk
Factors” in our reports filed with the SEC or in a prospectus
supplement related to this prospectus for additional risks which
could adversely impact our business and financial performance.
Moreover, new risks regularly emerge and it is not possible for our
management to predict all risks, nor can we assess the impact of
all risks on our business or the extent to which any risk, or
combination of risks, may cause actual results to differ from those
contained in any forward-looking statements. All forward-looking
statements included in this prospectus and any accompanying
prospectus supplement are based on information available to us on
the date hereof or thereof. Except to the extent required by
applicable laws or rules, we undertake no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. All subsequent
written and oral forward-looking statements attributable to us or
persons acting on our behalf are expressly qualified in their
entirety by the cautionary statements contained throughout (or
incorporated by reference in) this prospectus, any accompanying
prospectus and the documents we have filed with the
SEC.
PROSPECTUS
SUMMARY
The following summary highlights selected information contained or
incorporated by reference in this prospectus. This summary does not
contain all of the information you should consider before investing
in the securities. Before making an investment decision, you should
read the entire prospectus and any supplement hereto carefully,
including the risk factors section as well as the financial
statements and the notes to the financial statements incorporated
herein by reference.
In this prospectus and any amendment or supplement hereto, unless
otherwise indicated, the terms “Cellular Biomedicine Group,
Inc.,” “CBMG,” the “Company,”
“we,” “us,” and “our” refer and
relate to Cellular Biomedicine Group, Inc. and its consolidated
subsidiaries.
Our
Company
Cellular
Biomedicine Group, Inc. is a clinical stage biopharmaceutical
company, principally engaged in the development of novel therapies
for cancer and degenerative diseases utilizing proprietary
cell-based technologies. Our technology includes two major
platforms: (i) immune cell therapy for treatment of a broad range
of cancer indications comprised of technologies in Chimeric Antigen
Receptor modified T cells (CAR-T), T-Cell Receptor(TCR), cancer
vaccine, and ex vivo expanded autologous Central Memory T Cells
(Tcm), and (ii) human adipose-derived mesenchymal progenitor cells
(haMPC) for treatment of joint and autoimmune diseases. Our
research & development facilities and manufacturing facilities
are based in China in the cities of Shanghai, Wuxi and
Beijing.
We are focused on
developing and marketing safe and effective cell-based therapies
based on our cellular platforms, to treat cancer, orthopedic
diseases and metabolic diseases. We have developed proprietary
technologies and know-hows for our cell therapy platforms. Our
primary target market is Greater China. We believe that our
cell-based therapies will be able to help patients with high unmet
needs. We expect to carry out clinical studies leading to the
eventual CFDA approval of our products through Biologics License
Application (“BLA”) filings and authorized clinical
centers throughout Greater China.
We have launched
multiple clinical trials using our CAR-T products in multiple
indications such as Diffuse Large B-cell Lymphoma (DLBCL) and Acute
Lymphoblastic leukemia (ALL). We may also establish partnerships
with other companies for co-development of CAR-T, TCR-T and stem
cell based therapies. We are striving to build a highly competitive
research and development function, a translational medicine unit,
along with a well-established cellular manufacturing capability and
ample capacity, to support the development of multiple assets in
multiple indications. These efforts will allow us to boost the
Company's immuno-oncology presence and pave the way for additional
future partnerships.
Recent Developments
In January 2016, we
launched a Phase I clinical trial of an off-the-shelf allogeneic
haMPC AlloJoin™ therapy for KOA (the “Allogenic KOA
Phase I Trial”) to evaluate the safety and efficacy of
AlloJoin™, an off-the-shelf allogeneic adipose derived
progenitor cell (haMPC) therapy for the treatment of
KOA.
On March 23, 2016,
we filed a Form S-3 Registration Statement (the “S-3
Registration Statement”) with the SEC, which was declared
effective on June 17, 2016. The S-3 Registration Statement
contained three prospectuses:
●
Offering
Prospectus. A base prospectus which covers the offering, issuance
and sale by us of up to $150,000,000 of our common stock, preferred
stock, debt securities, warrants, rights and/or units;
●
Resale
Prospectus. A prospectus to be used for the resale by the selling
stockholders of up to 3,824,395 shares of the Common Stock;
and
●
Sales
Agreement Prospectus. A sales agreement prospectus covering the
offering, issuance and sale by the registrant of up to a maximum
aggregate offering price of $50,000,000 of the Common Stock that
may be issued and sold under a sales agreement with Cantor
Fitzgerald & Co.
On August 5, 2016,
we completed patient treatment for the Allogenic KOA Phase I Trial.
On December 9, 2016, we announced interim 3-month safety data from
the Allogenic KOA Phase I Trial in China. Preliminary results from
interim analysis have demonstrated a safety and tolerability
profile of AlloJoinTM in the three doses tested, and no serious
adverse events (SAE) have been observed. The trial has been
completed and we are analyzing the results on cartilage
regeneration as well as recent development in the competitive
landscape.
On November 29,
2016, we announced the approval and commencement of patient
enrollment in China for our CARD-1 (CAR-T Against DLBCL) Phase I
clinical trial of CD19 CAR-T therapy utilizing our optimized
proprietary C-CAR011 construct for the treatment of patients with
refractory DLBCL. The CARD-1 trial has begun enrollment with more
data expected to be available in the first half of
2018.
On December 9,
2016, we announced interim 3-month safety data from our Phase I
clinical trial in China for AlloJoin™ off-the-shelf
allogeneic stem cell therapy for KOA. The preliminary data was
presented in December 2016 at the World Stem Cell Summit in West
Palm Beach, Florida. The interim analysis of the trial has
preliminarily demonstrated a safety and tolerability profile of
AlloJoin™ in the three doses tested, and adverse events (AE)
are similar to that of our prior autologous trials. No serious
adverse events (SAE) have been observed.
On January 3, 2017,
we announced the signing of a ten-year lease of an 113,038-square
foot building located in the “Pharma Valley” in
Shanghai Zhangjiang High-Tech Park. The new facility designed and
built to GMP standards will consist of 40,000 square feet dedicated
to advanced cell manufacturing. We plan to invest an aggregate of
approximately $35 million into the Zhangjiang facility, of which
$10 million will be spent on to bring the facility into compliance
with current GMP standards and around 25 million will be spent on
lease of this real estate. By the end of 2017, the combination of
new Zhangjiang facility, an expanded Wuxi, and Beijing facilities,
all meeting international GMP standards, of the Company had
provided 70,000 square feet for cell manufacturing. The Company
expects that it will be capable of supporting clinical trials for
five different CART and stem cell products simultaneously, or the
ability to produce products to treat approximately 10,000 cancer
patients and 10,000 KOA patients per year. To reach this capacity,
we plan to hire an additional 60 R&D and Manufacturing
personnel by end of 2018.
On January 9, 2017,
we announced the commencement of patient enrollment in China for
our CALL-1 (CAR-T against Acute Lymphoblastic Leukemia) Phase I
clinical trial of CD19 CAR-T therapy utilizing its optimized
proprietary C-CAR011 construct for the treatment of patients with
relapsed or refractory (r/r) CD19+ B-cell ALL. The CALL-1 trial
began enrollment with more data expected to be available in the
first half of 2018. Depending on the Phase I CALL-1 results, CBMG
expects to initiate a larger Phase II clinical trial as soon as
possible.
On February 27,
2017 we announced the Company received a $2.29 million grant from
California Institute of Regenerative Medicine (CIRM) to fund our
off-the-shelf AlloJoin™ Allogeneic Stem Cell Therapy for KOA
in the United States. On May 4, 2017, the Company received $1.2
million from the CIRM grant, the first of four disbursements
totaling $2.29 million grant.
On March 30, 2017
we announced the completion of our newly expanded 30,000-square
foot facility in Huishan High Tech Park in Wuxi, China. 20,000
square feet of the Wuxi facility will be dedicated to advanced stem
cell culturing, centralized plasmid and viral vector production,
cell banking and development of reagents.
On April 10, 2017,
we announced a strategic research collaboration to co-develop
certain high-quality industrial control processes in CAR-T and stem
cell manufacturing with GE Healthcare Life Science. In connection
with the collaboration, a joint laboratory within CBMG’s new
Shanghai Zhangjiang facility designed and built to GMP standards
will be established and dedicated to the joint research and
development of a functionally integrated and automated
immunotherapy cell manufacturing system.
On May 15, 2017, we
announced the addition of a new independent Phase I clinical trial
of the Company’s ongoing CARD-1 study in patients with
chemorefractory or refractory B cell Non-Hodgkin Lymphoma (NHL).
The Company and Shanghai Tongji Hospital are conducting a single
arm, non-randomized study to evaluate the safety and efficacy of
C-CAR011 (Anti-CD19 single-chain variable fragment (scFv)
(41BB-CD3f)) therapy in relapsed or refractory B cell NHL patients.
The trial will enroll 15 patients comprised of DLBCL, Primary
Mediastinal Large B-Cell Lymphoma (PMBCL) and Follicular Lymphoma
(FL).
On June 1, 2017, we
announced our Board of Directors has approved a new stock
repurchase program granting the company authority to repurchase up
to $10 million in common shares (the “2017 Stock Repurchase
Program”) through open market purchases pursuant to a plan
adopted in accordance with Rule 10b5-1 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) and in
accordance with Rule 10b-18 of the Exchange Act. The 2017 Stock
Repurchase Program contemplates repurchase shares of our common
stock in the open market in accordance with all applicable
securities laws and regulations. From June to December 2017, we
repurchased a total of 426,794 shares at a total cost of
$3,977,929, or an average of $9.32 per share.
On June 20, 2017,
we announced the establishment of an External Advisory Board and
the appointment of Michael A. Caligiuri, MD, as Chair of the
External Advisory Board to bring together experts from diverse
disciplines to provide knowledge and insight to help CBMG fulfill
its mission and build a network for development opportunities. On
November 28, 2017, Dr. Caligiuri was appointed as President and
physician-in-chief of City of Hope National Medical
Center.
On November 4,
2017, we announced the grand opening of our Zhangjiang facility. On
the same day, we announced the signing of a strategic partnership
with Thermo Fisher Scientific (China) Ltd. to build a joint Cell
Therapy Technology Innovation and Application Center (Center) at
CBMG’s newly opened Shanghai Zhangjiang GMP
facility.
In December 2017,
we announced the closing of two private placement transactions
pursuant to which we sold an aggregate of 1,208,333 shares of our
common stock to certain key executives and private investors at
$12.00 per share, for total aggregate gross proceeds of
approximately $14.5 Million.
On January 30, 2018
and February 5, 2018, we entered into securities purchase
agreements with certain investors pursuant to which we agreed to
sell, and the investors agreed to purchase from the Company, an
aggregate of 1,719,324 shares of our common stock at $17.80 per
share for total gross proceeds of approximately $30.6 million (the
“February 2018 Private Placement”). The transaction
closed on February 5, 2018. Pursuant to the purchase agreements,
the investors have the right to nominate one director to the board
of directors of the Company to stand for election at the 2018
Annual Meeting of Stockholders. Effective as of the closing of the
February 2018 Private Placement, Bosun S. Hau was elected as a
non-executive Class III director of the Company.
In March 2018, we
announced 48-week clinical data from our Phase I clinical trial in
China for AlloJoin™ for KOA. The 48-week analysis of
study data of 22 patients demonstrated AlloJoin™
off-the-shelf allogeneic stem cell therapy for KOA to have good
safety tolerance and early signs of efficacy in preventing
cartilage deterioration. Effective March 14, 2018, our
CIRM project in the United States also
terminated. The two AlloJoin™ cell
banks created in the United States will be stored in the
Company’s Maryland facility for future
use.
Biopharmaceutical Business
Our
biopharmaceutical business was founded in 2009 as a newly formed
specialty biomedicine company by a team of seasoned
Chinese-American executives, scientists and doctors. In 2010, we
established a facility designed and built to GMP standards in Wuxi,
and in 2012 we established a FDA GMP standard protocol-compliant
manufacturing facility in Shanghai. In October 2015, we opened a
facility designed and built to GMP standards in Beijing. In
November 2017, we announced the grand opening of our Zhangjiang
facility in Shanghai, of which 40,000 square feet was designed and
built to GMP standards and dedicated to advanced cell
manufacturing. Our focus has been to serve the rapidly growing
health care market in China by marketing and commercializing stem
cell and immune cell therapeutics, related tools and products from
our patent-protected homegrown and acquired cell technology, as
well as by utilizing exclusively in-licensed and other acquired
intellectual properties.
Our current
treatment focal points are cancer and other degenerative diseases
such as KOA.
Cancer. In the cancer field, with the
recent build-up of multiple cancer therapeutic technologies, we
have prioritized our clinical efforts on CAR-T. We are not actively
pursuing the fragmented Tcm technical services opportunities. On
November 29, 2016, we announced the approval and commencement of
patient enrollment in China for its CARD-1 Phase I clinical trial
utilizing its optimized proprietary C-CAR011 construct of CD19
CAR-T therapy for the treatment of patients with refractory DLBCL.
The CARD-1 trial has begun enrollment with final data expected to
be available in the second half of 2018. On January 9, 2017 we
announced the approval and commencement of patient enrollment in
China for its CALL-1 Phase I clinical trial utilizing its optimized
proprietary C-CAR011 construct of CD19 CAR-T therapy for the
treatment of patients with relapsed or refractory (r/r) CD19+
B-cell ALL. The CALL-1 trial has begun enrollment with final data
expected to be available in the second half of 2018. Depending on
the Phase I CARD-1 and CALL-1 results, we expect to initiate larger
trials to confirm the safety and efficacy profile and support BLA
submission as soon as practicable.
On May 15, 2017, we
announced the addition of a new independent Phase I clinical trial
of the Company’s ongoing CARD-1 study in patients with
chemorefractory and aggressive DLBCL. Recruitment has started on
patients comprised of DLBCL, PMBCL and FL. Final data for this
single arm, non-randomized study to evaluate the safety and
efficacy of C-CAR011 41BB-CD3f therapy in relapsed or refractory B
cell NHL is expected in the first half of 2019.
KOA. In 2013, we completed a Phase
I/IIa clinical study in China for our KOA therapy named
Re-Join®. The trial tested the safety and efficacy of
intra-articular injections of autologous haMPCs in order to reduce
inflammation and repair damaged joint cartilage. The 6-month
follow-up clinical data showed Re-Join® therapy to be both
safe and effective.
In Q2 of 2014, we
completed patient enrollment for the Phase IIb clinical trial of
Re-Join® for KOA. The multi-center study enrolled 53 patients
to participate in a randomized, single blind trial. We published 48
weeks follow-up data of Phase I/IIa on December 5, 2014. The 48
week data indicated that patients have reported a decrease in pain
and a significant improvement in mobility and flexibility, while
the clinical data shows our Re-Join® regenerative medicine
treatment to be safe. We announced the interim 24 week results for
Re-Join® on March 25, 2015 and released positive Phase IIb 48
week follow-up data in January 2016, which shows the primary and
secondary endpoints of Re-Join® therapy group having all
improved significantly compared to their baseline, which has
confirmed some of the Company’s Phase I/IIa results. Our
Re-Join® haMPC therapy for KOA is an interventional therapy
using proprietary device, process, culture and medium:
●
Obtain
adipose (fat) tissue from the patient using our CFDA approved
medical device, the A-Stromal™ Kit;
●
Expand
haMPCs using our proprietary culture medium (serum-free and
antibiotics-free); and
●
Formulated for
ReJoin therapy using our proprietary formulation.
Our process is
distinguishable from sole Stromal Vascular Fraction (SVF) therapy.
The immunophenotype of our haMPCs exhibited multiple biomarkers
such as CD29+, CD73+, CD90+, CD49d+, HLA-I+, HLA-DR-, Actin-,
CD14-, CD34-, and CD45-. In contrast, SVF is merely a heterogeneous
fraction including preadipocytes, endothelial cells, smooth muscle
cells, pericytes, macrophages, fibroblasts, and adipose-derived
stem cells (ASCs).
In January 2016, we
launched the Allogeneic KOA Phase I Trial in China to evaluate the
safety and efficacy of AlloJoin™, an off-the shelf allogeneic
haMPC therapy for the treatment of KOA. On August 5, 2016 we
completed patient treatment for the Allogeneic KOA Phase I trial,
and on December 9, 2016 we announced interim 3-month safety data
from the Allogenic KOA Phase I Trial in China. The interim analysis
of the trial has preliminarily demonstrated a safety and
tolerability profile of AlloJoin™ in the three doses tested,
and no SAE have been observed. In March 2018, we announced 48-week
clinical data from our Phase I clinical trial in China for
AlloJoin™ for KOA. The 48-week analysis of study data of 22
patients demonstrated AlloJoin™ off-the-shelf allogeneic stem
cell therapy for KOA to have good safety tolerance and early signs
of efficacy in preventing cartilage deterioration. The total WOMAC
scores (consisting of pain, stiffness and function scores of
joints) as a primary end point showed a significant improvement at
12 weeks post AlloJoin™ cell therapy and continued
improvement at 48 weeks. The secondary evaluation end point, the
data of 3D spoiled gradient-recalled echo (SPGR) quantitative
magnetic resonance imaging (MRI) for whole knee cartilage volume at
48 weeks, showed an increased tendency when compared with that at
baseline 0 weeks, and as compared with normal cartilage
deterioration as a result of aging.
In January 2015, we
initiated patient recruitment in a phase II clinical study, in
China, of ReJoin haMPC in Cartilage Damaged patients resulting from
osteoarthritis or sports injury, in further support of KOA
indication. The study is based on the same technology that has
shown significant efficacy in the treatment of KOA but requires two
arthroscopic examinations and the use of magnetic resonance imaging
(“MRI”) to further demonstrate the regenerative
efficacy of ReJoin. Upon further review of the protocol and the
difficulty of getting patients back for a second arthroscopic
examination, we determined to terminate the study.
The unique lines of
adult adipose-derived stem cells and the immune cell therapies
enable us to create multiple cell formulations in treating specific
medical conditions and diseases, as well as applying single cell
types in a specific treatment protocol. The quality management
systems of CBMG Shanghai and CBMG Wuxi were issued a Certificate of
ISO-9001:2008 by SGS /ANAB (ANSI-ASQ National Accreditation Board).
Our facility in Shanghai was issued a Certificate of Compliance by
ENV Services, Inc., and ISO Inspection Service Provider that (i)
its rooms 1-7, 10 are certified to ISO Class 7 per ISO-14644 in
accordance with cGMP; (ii) its biological safety cabinets are
certified per NSF/ANSI 49 and to ISO Class 5;and (iii) its
instrumentation calibration has been certified to perform in
accordance with ANSI/NCSL Z-540-1 and document in accordance with
10CFR21. Our facility in Shanghai was issued a Testing Report
concluding that certain testing items of our Shanghai
facility’s cleanrooms are in compliance with the Good
Manufacturing Practice for Drugs (2010 Revision) of China. The
cleanrooms in our Beijing facility are certified to meet the
standard of CNAS L1669 and the cleanrooms of our Wuxi facility have
been certified to meet the SHPMCC standard.
In addition to
standard protocols, we use proprietary processes and procedures for
manufacturing our cell lines, comprised of:
●
Banking
processes that ensure cell preservation and viability;
●
DNA
identification for stem cell ownership; and
●
Bio-safety testing
at independently certified laboratories.
Regenerative Medicine and Cell Therapy
Regenerative
medicine is the “process of replacing or regenerating human
cells, tissues or organs to restore or establish normal
function”. Cell therapy as applied to regenerative medicine
holds the promise of regenerating damaged tissues and organs in the
body by rejuvenating damaged tissue and by stimulating the
body’s own repair mechanisms to heal previously irreparable
tissues and organs. Medical cell therapies are classified into two
types: allogeneic (cells from a third-party donor) or autologous
(cells from one’s own body), with each offering its own
distinct advantages. Allogeneic cells are beneficial when the
patient’s own cells, whether due to disease or degeneration,
are not as viable as those from a healthy donor. Similarly, in
cases such as cancer, where the disease is so unique to the
individual, autologous cells can offer true personalized
medicine.
Regenerative
medicine can be categorized into major subfields as
follows:
●
Cell
Therapy. Cell therapy involves the use of cells, whether derived
from adults, third party donors or patients, from various parts of
the body, for the treatment of diseases or injuries. Therapeutic
applications may include cancer vaccines, cell based
immuno-therapy, arthritis, heart disease, diabetes,
Parkinson’s and Alzheimer’s diseases, vision
impairments, orthopedic diseases and brain or spinal cord injuries.
This subfield also includes the development of growth factors,
serums and natural reagents that promote and guide cell
development.
●
Tissue
Engineering. This subfield involves using a combination of cells
with biomaterials (also called “scaffolds”) to generate
partially or fully functional tissues and organs, or using a
mixture of technology in a bioprinting process. Some natural
materials, like collagen, can be used as biomaterial, but advances
in materials science have resulted in a variety of synthetic
polymers with attributes that would make them uniquely attractive
for certain applications. Therapeutic applications may include
heart patch, bone re-growth, wound repair, replacement neo-urinary
conduits, saphenous arterial grafts, inter-vertebral disc and
spinal cord repair.
●
Diagnostics and Lab
Services. This subfield involves the production and derivation of
cell lines that may be used for the development of drugs and
treatments for diseases or genetic defects. This sector also
includes companies developing devices that are designed and
optimized for regenerative medicine techniques, such as specialized
catheters for the delivery of cells, tools for the extraction of
stem cells and cell-based diagnostic tools.
All living complex
organisms start as a single cell that replicates, differentiates
(matures) and perpetuates in an adult through its lifetime. Cell
therapy is aimed at tapping into the power of cells to prevent and
treat disease, regenerate damaged or aged tissue and provide
cosmetic applications. The most common type of cell therapy has
been the replacement of mature, functioning cells such as through
blood and platelet transfusions. Since the 1970s, bone marrow and
then blood and umbilical cord-derived stem cells have been used to
restore bone marrow and blood and immune system cells damaged by
chemotherapy and radiation used to treat many cancers. These types
of cell therapies have been approved for use world-wide and are
typically reimbursed by insurance.
Over the past
number of years, cell therapies have been in clinical development
to attempt to treat an array of human diseases. The use of
autologous (self-derived) cells to create vaccines directed against
tumor cells in the body has been demonstrated to be effective and
safe in clinical trials. Researchers around the globe are
evaluating the effectiveness of cell therapy as a form of
replacement or regeneration of cells for the treatment of numerous
organ diseases or injuries, including those of the brain and spinal
cord. Cell therapies are also being evaluated for safety and
effectiveness to treat heart disease, autoimmune diseases such as
diabetes, inflammatory bowel disease, joint diseases and cancerous
diseases. While no assurances can be given regarding future medical
developments, we believe that the field of cell therapy is a subset
of biotechnology that holds promise to improve human health, help
eliminate disease and minimize or ameliorate the pain and suffering
from many common degenerative diseases relating to
aging.
Recent Developments in Cancer Cell Therapy
According to the
U.S. National Cancer Institute’s 2013 cancer topics research
update on CAR-T-Cells, excitement is growing for
immunotherapy—therapies that harness the power of a
patient’s immune system to combat their disease, or what some
in the research community are calling the “fifth
pillar” of cancer treatment.
One approach to
immunotherapy involves engineering patients’ own immune cells
to recognize and attack their tumors. And although this approach,
called adoptive cell transfer ("ACT"), has been restricted to small
clinical trials so far, treatments using these engineered immune
cells have generated some remarkable responses in patients with
advanced cancer. For example, in several early-stage trials testing
ACT in patients with ALL who had few if any remaining treatment
options, many patients’ cancers have disappeared entirely.
Several of these patients have remained cancer free for extended
periods.
Equally promising
results have been reported in several small clinical trials
involving patients with lymphoma. Although the lead investigators
cautioned that much more research is needed, the results from the
trials performed thus far indicate that researchers can
successfully alter patients’ T cells so that they attack
their cancer cells. As an example, we look to Spectrum
Pharmaceutical’s Folotyn approved in September 2009 for
treatment of R/R peripheral T-cell lymphoma with approval supported
by a single arm trial observing an overall response rate of 27% and
median duration of response of 9.4 months. In addition, CTI
Therapeutics Pixuvri received a complete response letter in April
2010 in R/R aggressive NHL in which a 37% overall response rate and
5.5 month duration of response was observed.
ACT’s
building blocks are T cells, a type of immune cell collected from
the patient’s own blood. After collection, the T cells are
genetically engineered to produce special receptors on their
surface called chimeric antigen receptors ("CARs"). CARs are
proteins that allow the T cells to recognize a specific protein
(antigen) on tumor cells. These engineered CAR T cells are then
grown in the laboratory until they number in the billions. The
expanded population of CAR T cells is then infused into the
patient. After the infusion, if all goes as planned, the T cells
multiply in the patient’s body and, with guidance from their
engineered receptor, recognize and kill cancer cells that harbor
the antigen on their surfaces. This process builds on a similar
form of ACT pioneered from NCI’s Surgery Branch for patients
with advanced melanoma. According to www.cancer.gov, in 2013,
NCI’s Pediatric Oncology Branch commented that the CAR T
cells are much more potent than anything they can achieve with
other immune-based treatments being studied. Although investigators
working in this field caution that there is still much to learn
about CAR T-cell therapy, the early results from trials like these
have generated considerable optimism. Researchers opined that CAR
T-cell therapy eventually may become a standard therapy for some
B-cell malignancies like ALL and chronic lymphocytic
leukemia.
So
far, chimeric antigen receptor T cell therapy such as CD19 CAR-T,
have been tested in several hematological indications on patients
that are refractory/relapsing to chemotherapy, and many of them
have relapsed after stem cell transplantation. All of these
patients had very limited treatment option prior to CAR-T therapy.
CAR-T has shown positive clinical efficacy in many of these
patients. Some of have them lived for years post CAR-T treatment.
Management believes the remaining risk in monetizing cancer immune
cell therapies is concentrated in late stage clinical studies,
speed-to-approval, manufacturing and process
optimization.
On July 2016, Juno
Therapeutics, Inc. reported the death of patients enrolled in the
U.S. Phase II clinical trial of JCAR015 for the treatment of
relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL).
The US FDA put the trial on hold and lifted the hold within a week
after Juno provided satisfactory explanation and solution. Juno
believes that the patient deaths were caused by the use of
Fludarabine preconditioning and they will use only cyclophosphamide
pre-conditioning in the future enrollment. The trial was halted in
November of 2016 after two more deaths occurred after the trial
resumed. The Company believes that its product and study are
distinguishable from Juno Therapeutics and plans to continue to
monitor any toxicities associated with the study.
In August 2017, the
FDA approved Novartis’ CAR-T therapy on relapsed or
refractory (r/r) acute lymphoblastic leukemia (ALL), the most
common cancer in Children. Current treatments show a rate of 80%
remission using intensive chemotherapy. However, there are almost
no conventional treatments to help patients who have relapsed.
Novartis’ Tisagenlecleucel (Kymriah), a CD19-targeted CAR-T
therapy for children and adolescents with r/r ALL has shown results
of complete and long lasting remission, which led the FDA to
approve the drug funded by Novartis and the first CAR-T
therapy.
In October 2017,
the FDA approved Kite Pharmaceuticals’ (Gilead) CAR-T therapy
for DLBCL, the most common type of NHL in adults. The initial
results of axicabtagene ciloleucel (Yescarta), Kite Pharma’s
drug for NHL, shows four out of seven patients treated achieved
complete remission, which continued after 12 months. The prognosis
of high-grade chemo refractory NHL is dismal with a medium survival
time of a few weeks. Yescarta is a therapy for patients who have
not responded to or who have relapsed after at least two other
kinds of treatment.
In December 2017,
the Chinese government issued trial guidelines concerning the
development of cell therapy products in China. Although these trial
guidelines are not yet codified as mandatory regulations, we
believe they provide a measure of clarity and a preliminary
regulatory pathway for our cell therapy operations in a still
uncertain regulatory environment.
Market for Cell-Based Therapies
In 2013, U.S. sales
of products which contain stem cells or progenitor cells or which
are used to concentrate autologous blood, bone marrow or adipose
tissues to yield concentrations of stem cells for therapeutic use
were, conservatively, valued at $236 million at the hospital level.
It is estimated that the orthopedics industry used approximately
92% of the stem cell products.
The forecast is
that in the United States, shipments of treatments with stem cells
or instruments which concentrate stem cell preparations for
injection into painful joints will fuel an overall increase in the
use of stem cell based treatments and an increase to $5.7 billion
in 2020, with key growth areas being Spinal Fusion, Sports Medicine
and Osteoarthritis of the joints. According to Centers for Disease
Control and Prevention. Prevalence of doctor-diagnosed arthritis
and arthritis-attributable activity limitation United States.
2010-2012, Osteoarthritis (OA) is a chronic disease that is
characterized by degeneration of the articular cartilage,
hyperosteogeny, and ultimately, joint destruction that can affect
all of the joints. According to Dillon CF, Rasch EK, Gu Q et al.
Prevalence of knee osteoarthritis in the United States: Arthritis
Data from the Third National Health and Nutrition Examination
Survey 1991-94. J Rheumatol. 2006, the incidence of OA is 50% among
people over age 60 and 90% among people over age 65. KOA accounts
for the majority of total OA conditions and in adults, OA is the
second leading cause of work disability and the disability
incidence is high (53%). The costs of OA management have grown
exponentially over recent decades, accounting for up to 1% to 2.5%
of the gross national product of countries with aging populations,
including the U.S., Canada, the UK, France, and Australia.
According to the American Academy of Orthopedic Surgeons (AAOS),
the only pharmacologic therapies recommended for OA symptom
management are non-steroidal anti-inflammatory drugs (NSAIDs) and
tramadol (for patients with symptomatic osteoarthritis). Moreover,
there is no approved disease modification therapy for OA in the
world. Disease progression is a leading cause of hospitalization
and ultimately requires joint replacement surgery. In 2009, the
U.S. spent over $42 billion on replacement surgery for hip and knee
joints alone. International regulatory guidelines on clinical
investigation of medicinal products used in the treatment of OA
were updated in 2015, and clinical benefits (or trial outcomes) of
a disease modification therapy for KOA has been well defined and
recommended. Medicinal products used in the treatment of
osteoarthritis need to provide both a symptom relief effect for at
least 6 months and a structure modification effect to slow
cartilage degradation by at least 12 months. Symptom relief is
generally measured by a composite questionnaire Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) score, and
structure modification is measured by MRI, or radiographic image as
accepted by international communities. The Company uses the WOMAC
as primary end point to demonstrate symptom relief, and MRI to
assess structure and regeneration benefits as a secondary
endpoint.
According to the
Foundation for the National Institutes of Health, there are 27
million Americans with OA, and symptomatic KOA occurs in 13% of
persons aged 60 and older. The International Journal of Rheumatic
Diseases, 2011 reports that approximately 57 million people in
China suffer from KOA. Currently no treatment exists that can
effectively preserve knee joint cartilage or slow the progression
of KOA. Current common drug-based methods of management, including
anti-inflammatory medications (NSAIDs), only relieve symptoms and
carry the risk of side effects. Patients with KOA suffer from
compromised mobility, leading to sedentary lifestyles; doubling the
risk of cardiovascular diseases, diabetes, and obesity; and
increasing the risk of all causes of mortality, colon cancer, high
blood pressure, osteoporosis, lipid disorders, depression and
anxiety. According to the Epidemiology of Rheumatic Disease (Silman
AJ, Hochberg MC. Oxford Univ. Press, 1993:257), 53% of patients
with KOA will eventually become disabled.
The number of cell
therapy companies that are currently in Phase 2 and Phase 3 trials
has been gathering momentum, and we anticipate that new cellular
therapy products will appear on the market within the next several
years.
Our Targeted Indications and Potential Therapies
Knee Osteoarthritis (KOA)
We are currently
pursuing two primary therapies for the treatment of KOA: our
Re-Join ® therapy and our AlloJoinTM therapy.
We completed the
Phase I/IIa clinical trial for the treatment of KOA. The trial
tested the safety and efficacy of intra-articular injections of
autologous haMPCs in order to reduce inflammation and repair
damaged joint cartilage. The 6-month follow-up clinical data showed
Re-JoinTM therapy to be both safe and effective.
In the second
quarter of 2014, we completed patient enrollment for the Phase IIb
clinical trial of Re-Join® for KOA. The multi-center study has
enrolled 53 patients to participate in a randomized, single blind
trial. We published 48 weeks follow-up data of Phase I/IIa on
December 5, 2014. The 48 weeks data indicated that patients have
reported a decrease in pain and a significant improvement in
mobility and flexibility, while the clinical data shows our
Re-Join® regenerative medicine treatment to be safe. We
announced positive Phase IIb 48-week follow-up data in January
2016, with statistical significant evidence that Re-Join®
enhanced cartilage regeneration, which concluded the planned phase
IIb trial.
In January 2016, we launched the Allogeneic KOA
Phase I Trial in China to
evaluate the safety and efficacy of AlloJoin™, an off-the
haMPC therapy for the treatment of KOA. On August 5, 2016 we
completed patient treatment for the Allogeneic KOA Phase I trial. On August 5,
2016 we completed patient treatment for the Allogenic KOA Phase I
Trial, and on December 9, 2016, we announced interim 3-month safety
data from the Allogenic KOA Phase I Trial in China. The interim
analysis of the trial has preliminarily demonstrated a safety and
tolerability profile of AlloJoin™ in the three doses tested,
and no serious adverse events (SAE) have been observed. In March
2018, we announced 48-week clinical data from our Phase I clinical
trial in China for AlloJoin™ for KOA. The 48-week analysis of
study data of 22 patients demonstrated AlloJoin™
off-the-shelf allogeneic stem cell therapy for KOA to have good
safety tolerance and early signs of efficacy in preventing
cartilage deterioration. The total WOMAC scores (consisting of
pain, stiffness and function scores of joints) as a primary end
point showed a significant improvement at 12 weeks post
AlloJoin™ cell therapy and continued improvement at 48 weeks.
The secondary evaluation end point, the data of 3D spoiled
gradient-recalled echo (SPGR) quantitative magnetic resonance
imaging (MRI) for whole knee cartilage volume at 48 weeks, showed
an increased tendency when compared with that at baseline 0 weeks,
and as compared with normal cartilage deterioration as a result of
aging.
Osteoarthritis is a
degenerative disease of the joints. KOA is one of the most common
types of osteoarthritis. Pathological manifestation of
osteoarthritis is primarily local inflammation caused by immune
response and subsequent damage of joints. Restoration of immune
response and joint tissues are the objective of
therapies.
According to
International Journal of Rheumatic
Diseases, 2011, 53% of KOA patients will degenerate to the
point of disability. Conventional treatment usually involves
invasive surgery with painful recovery and physical therapy. As
drug-based methods of management are ineffective, the same journal
estimates that some 1.5 million patients with this disability will
degenerate to the point of requiring artificial joint replacement
surgery every year. However, only 40,000 patients will actually be
able to undergo replacement surgery, leaving the majority of
patients to suffer from a life-long disability due to lack of
effective treatment.
haMPCs are
currently being considered as a new and effective treatment for
osteoarthritis, with a huge potential market. Osteoarthritis is one
of the ten most disabling diseases in developed countries.
Worldwide estimates are that 9.6% of men and 18.0% of women aged
over 60 years have symptomatic osteoarthritis. It is estimated that
the global OA therapeutics market was worth $4.4 billion in 2010
and is forecast to grow at a compound annual growth rate
(“CAGR”) of 3.8% to reach $5.9 billion by
2018.
In order to bring
haMPC-based KOA therapy to market, our market strategy is to: (a)
establish regional laboratories that comply with cGMP standards in
Shanghai and Beijing that meet Chinese regulatory approval; and (b)
file joint applications with Class AAA hospitals to use haMPCs to
treat KOA in a clinical trial setting.
Our competitors are
pursuing treatments for osteoarthritis with knee cartilage
implants. However, unlike their approach, our KOA therapy is not
surgically invasive. It uses a small amount (30ml) of adipose
tissue obtained via liposuction from patients, which is cultured
and re-injected into the patient. The injections are designed to
induce the body’s secretion of growth factors promoting
immune response and regulation, and regrowth of cartilage. The
down-regulation of the patient’s immune response is aimed at
reducing and controlling inflammation which is a central cause of
KOA.
We believe our
proprietary method, subsequent haMPC proliferation and processing
know-how will enable haMPC therapy to be a low cost and relatively
safe and effective treatment for KOA. Additionally, banked haMPCs
can continue to be stored for additional use in the
future.
Immuno-oncology (I/o)
We continue to
fortify our cancer breakthrough technology platform with I/o,
programmed cell death and vaccine technology.
Our CAR-T platform
is built on lenti-virial vector and second-generation CAR design,
which is used by most of the current trials and studies. We
rigorously select the patient population for each asset and
indication to allow the optimal path forward for regulatory
approval. We also fully integrate the state of art translational
medicine effort into each clinical study to aid in dose selection,
to confirm the mechanism of action and proof of concept, and to
identify the optimal targeting patient population whenever
appropriate. We plan to continue to grow our translational medicine
team and engage key opinion leaders to meet the
demand.
Solid tumors pose
more challenges than hematological cancers. The patients are more
heterogeneous, making it difficult to have one drug to work
effectively in the majority of the patients in any cancer
indication. The duration of response is most likely shorter and
patients are likely to relapse even after initial positive clinical
response. We will continue our efforts in developing cell based
therapies to target both hematological cancers and solid
tumors.
Human Adipose-Derived Mesenchymal Progenitor Cells
(haMPC)
Adult mesenchymal
stem cells can currently be isolated from a variety of adult human
sources, such as liver, bone marrow, and adipose (fat) tissue. We
believe the advantages in using adipose tissue (as opposed to bone
marrow or blood) are that it is one of the richest sources of
pluripotent cells in the body, the easy and repeatable access to
fat via liposuction, and the simple cell isolation procedures that
can begin to take place even on-site with minor equipment needs.
The procedure we are testing for KOA involves extracting a very
small amount of fat using a minimally invasive extraction process
which takes up to 20 minutes, and leaves no scarring. The haMPC
cells are then processed and isolated on site, and injected intra
articularly into the knee joint with ultrasound
guidance.
These haMPC cells
are capable of differentiating into bone, cartilage, tendon,
skeletal muscle, and fat under the right conditions. As such,
haMPCs are an attractive focus for medical research and clinical
development. Importantly, we believe both allogeneic and
autologously sourced haMPCs may be used in the treatment of
disease. Numerous studies have provided preclinical data that
support the safety and efficacy of allogeneic and autologously
derived haMPC, offering a choice for those where factors such as
donor age and health are an issue.
Additionally,
certain disease treatment plans call for an initial infusion of
these cells in the form of SVF, an initial form of cell isolation
that can be completed and injected within ninety minutes of
receiving lipoaspirate. The therapeutic potential conferred by the
cocktail of ingredients present in the SVF is also evident, as it
is a rich source for preadipocytes, mesenchymal stem cells,
endothelial progenitor cells, T regulatory cells and
anti-inflammatory macrophages.
Tumor Cell Specific Dendritic Cells (TC-DC)
Recent scientific
findings indicate the presence of special cells in tumors that are
responsible for cancer metastases and relapse. Referred to as
“cancer stem cells”, these cells make up only a small
portion of the tumor mass. The central concept behind TC-DC therapy
is to immunize against these cells. TC-DC therapy takes a sample of
the patient’s own purified and irradiated cancer cells and
combines them with specialized immune cells, thereby
‘educating’ the immune cells to destroy the cancer stem
cells from which tumors arise. We believe the selective targeting
of cells that drive tumor growth would allow for effective cancer
treatment without the risks and side effects of current therapies
that also destroy healthy cells in the body.
Our Strategy
The majority of our
biopharmaceutical business is in the development stage. We intend
to concentrate our business on cell therapies and in the near-term,
carrying our KOA stem cell therapy and cancer immune cell therapies
to commercialization.
We are developing
our business in cell therapeutics and capitalizing on the
increasing importance and promise that adult stem cells have in
regenerative medicine. Our most advanced candidate involves
adipose-derived mesenchymal stem cells to treat KOA. Based on
current estimates, we expect our biopharmaceutical business to
generate revenues primarily through the development of therapies
for the treatment of KOA within the next three to four
years.
Presently we have
two completed KOA cell therapy clinical studies in China, a Phase
IIb autologous study and a Phase I allogeneic study. If and when
either therapy obtains regulatory approval in the PRC, we will be
able to market and offer the therapy for clinical use in
China.
Our strategy is to
develop safe and effective cellular medicine therapies for
indications that represent a large unmet need in China, based on
technologies developed both in-house and obtained through
acquisition, licensing and collaboration arrangements with other
companies. Our near term objective is to pursue successful clinical
trials in China for our KOA application. We intend to utilize our
comprehensive cell platform to support multiple cell lines to
pursue multiple therapies, both allogeneic and autologous. We
intend to apply U.S. Standard Operating Procedures ("SOPs") and
protocols while complying with Chinese regulations, while owning,
developing and executing our own clinical trial protocols. We plan
to establish domestic and international joint ventures or
partnerships to set up cell laboratories and/or research
facilities, acquire technology or in-license technology from
outside of China, and build affiliations with hospitals, to develop
a commercialization path for our therapies, once approved. We
intend to use our first-mover advantage in China, against a
backdrop of enhanced regulation by the central government, to
differentiate ourselves from the competition and establish a
leading position in the China cell therapeutic market. We also
intend to out-license our technologies to interested
parties.
With the AG
acquisition we intend to monetize AG’s U.S. and Chinese
intellectual property for immune cell therapy preparation
methodologies and patient immunity assessment by engaging with
prominent hospitals to conduct pre-clinical and clinical studies in
specific cancer indications. The T Cell clonality analysis
technology patent, together with AG’s other know-hows for
immunity analysis, will enable us to establish an immunoassay
platform that is crucial for immunity evaluation of patients with
immune disorders as well as cancerous diseases that are undergoing
therapy. We will continue to seek to empower hospitals’
immune cell cancer development programs that help patients improve
their quality of life and survival rate.
We believe that few
competitors in China are as well-equipped as we are in the clinical
trial development, diversified FDA protocol compliant manufacturing
facilities, regulatory compliance and policy making participation,
as well as a long-term presence in the U.S. with U.S.-based
management and investor base.
We intend to
continue our business development efforts by adding other proven
domestic and international biotechnology partners to monetize the
China health care market.
In order to
expedite fulfillment of patient treatment, we have been actively
developing technologies and products with a strong intellectual
properties protection, including haMPC, derived from fat tissue,
for the treatment of KOA and other indications. Our acquisition of
AG provides an enlarged opportunity to expand the application of
its cancer therapy-enabling technologies and to initiate clinical
trials with leading cancer hospitals.
Our proprietary and
patent-protected production processes and clinical protocols enable
us to produce raw material, manufacture cells, and conduct cell
banking and distribution. These protocols include medical
assessment to qualify each patient for treatment, evaluation of
each patient before and after a specific therapy, cell
transplantation methodologies including dosage, frequency and the
use of adjunct therapies, potential adverse effects and their
proper management. Applying our proprietary intellectual property,
we will be able to customize specialize formulations to address
complex diseases and debilitating conditions.
We have been
developing disease-specific clinical treatment protocols. These
protocols are designed for each of these proprietary cell lines to
address patient-specific medical conditions. These protocols
include medical assessment to qualify each patient for treatment,
evaluation of each patient before and after a specific therapy,
cell transplantation methodologies including dosage, frequency and
the use of adjunct therapies, potential adverse effects and their
proper management.
The
protocol of allogeneic haMPC therapy for KOA has been approved by
Shanghai Renji Hospital’s Institutional Review Board for
clinical studies. Once the studies are completed, the clinical data
will be analyzed by qualified third party statisticians and reports
will be published.
We operate our
manufacturing facilities under the design of GMP conditions in the
ISO accredited laboratories standard. We employ an
institutionalized and proprietary process and quality management
system to optimize reproducibility and to hone our efficiency.
Three facilities designed and built to GMP in Beijing, Shanghai and
Wuxi, China meet international standards. With our integrated
Plasmid, Viral Vectors, and CART cells Chemistry,
Manufacturing, and Controls processes as well as planned capacity
expansion, we are highly distinguishable with other companies in
the cellular medicine space.
In total, our cGMP
facilities have approximately 70,000 sq. ft. of space and are
expected to have a capacity to treat approximately 10,000 cancer
patients and 10,000 patients per year.
Most importantly,
our most experienced team members have more than 20 years of
relevant experience in China, European Union, and the United
States. All of these factors make CBMG a high quality cell products
manufacturer in China.
In the next 12
months, we aim to accomplish the following, though there can be no
assurances that we will be able to accomplish any of these
goals:
●
Bolster R&D resources to fortify our
intellectual properties portfolio and scientific development.
Continue to develop a competitive Immuno-oncology pipeline for
CBMG. Seek opportunities to
file new patents in China and potentially the rest of the
world;
●
Continue
to identify and evaluate advanced technologies and seek
partnerships to bolster our competitive edge in the cell therapy
field in China;
●
Submit
to the CFDA an IND package for C-CAR011 in treating patients with
CD19+ B-cell malignancies.
●
Confirm
the safety and efficacy profile of C-CAR011 in China in refractory
aggressive DLBCL and to initiate a larger Phase II clinical trial
whenever feasible.
●
Confirm
the safety and efficacy of C-CAR011 in relapsed and refractory
(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) in China, and
/ to prepare for a follow up multicenter phase IIb
trial.
●
Initiate
an investigator sponsored phase I trial of anti-BCMA CART in adults
with relapsed/refractory multiple myeloma;
●
Implement
our GE Joint Technology Laboratory to develop control processes for
the manufacturing of CAR-T and Stem Cell Therapies;
●
Implement
steps to advance our Thermo Fisher joint Cell Therapy Technology
Innovation and Application Center;
●
Initiate
a clinical study to support the biological license application
(BLA) for autologous and allogeneic KOA study in
China;
●
Complete
Chemistry, Manufacturing and Controls (CMC), non-clinical and
preclinical study data package to prepare for Allogeneic KOA IND
filing in the United States;
●
Initiate
clinical study to support the BLA for allogeneic KOA study in the
United States;
●
Evaluate
new regenerative medicine technology platform for other indications
and review recent development in the competitive
landscape;
●
Evaluate
our corporate development strategy on maintaining the CAR-T and
regenerative medicine dual technology platform;
●
Evaluate
the feasibility and opportunities of novel Alpha Fetoprotein
Specific TCR to redirect T Cells for a Hepatocellular Carcinoma
(HCC) Immunotherapy;
●
Evaluate
the addition of cancer diagnostics to our business;
and
●
Improve
liquidity and fortify our balance sheet by courting institutional
investors.
Manufacturing
We manufacture
cells for our own research, testing and clinical trials. We are
scaling up and expanding our manufacturing capacity to treat up to
10,000 CAR-T and 10,000 KOA patients per year when our facilities
are fully operational by the end of 2018. Our facilities are
operated by a manufacturing and technology team with decades of
relevant experience in China, the EU and the United
States.
In any precision
setting, it is vital that all controlled environment equipment meet
certain design standards. We operate our manufacturing facilities
under GMP conditions in the ISO accredited laboratories standard.
We employ an institutionalized and proprietary process and quality
management system to optimize reproducibility and to hone our
efficiency. Three of our facilities designed and built to GMP in
Beijing, Shanghai and Wuxi, China meet international standards.
Specifically, our Shanghai cleanroom facility underwent rigorous
cleanroom certification since 2013. Our facility in Shanghai was
issued a Certificate of Compliance by ENV Services, Inc., an ISO
Inspection Service Provider, that (i) its rooms 1-7, 10 are
certified to ISO Class 7 per ISO-14644 in accordance with cGMP.
(ii) its biological safety cabinets are certified per NSF/ANSI 49
and to ISO Class 5. and (iii) its instrumentation calibration has
been certified to perform in accordance with ANSI/NCSL Z540-1 and
document in accordance with 10CFR21. The cleanrooms in Beijing are
certified to meet the standard of CNAS L1669 and our Wuxi facility
has been certified to meet the CNAS SHPMCC standard. With our
integrated Plasmid, Viral Vectors, and CAR-T cells Chemistry,
Manufacturing, and Controls processes as well as planned capacity
expansion, we believe that are highly distinguishable with other
companies in the cellular medicine space.
In January 2017, we
leased a 113,038-square foot building located in the “Pharma
Valley” of Shanghai, the People’s Republic of China. We
are establishing 43,000 square foot GMP facilities there with 25
clean-rooms and equipped with 12 independent production lines to
support clinical batch production and commercial scale
manufacturing. With above expansion, the Company could support up
to 10,000 patients with CAR-T therapy and 10,000 KOA patients with
the stem cell therapy per annum.
We have built cell
preparation and inspection laboratories that enable the following
mode of human body immune cell in-vitro culture service to be
provided: make cell preparation for human body venous blood
samples, after completion of the cell preparation, deliver the
immune cell agents to the customer; and provide immune function
evaluation for the patients in Jilin and several other hospitals in
China.
Competition
Many companies
operate in the cellular biopharmaceutical field. In 2010, the FDA
approved the first cell therapy for Dendreon Corporation to apply
an autologous cellular immunotherapy for the treatment of a certain
type of prostate cancer. In May 2012, the Canadian authorities
approved the first stem cell drug and granted Osiris
Therapeutics’ manufactured stem cell product for use in the
pediatric graft-versus-host disease. To date, there are over 30
publicly listed and several private cellular biopharmaceutical
focused companies outside of China with varying phases of clinical
trials addressing a variety of diseases. We compete with these
companies in bringing cellular therapies to the market. However,
our focus is to develop a core business in the China market. This
difference in focus places us in a different competitive
environment from other western companies with respect to fund
raising, clinical trials, collaborative partnerships, and the
markets in which we compete.
The PRC central
government has a focused strategy to enable China to compete
effectively in certain designated areas of biotechnology and the
health sciences. Because of the aging population in China,
China’s Ministry of Science and Technology
(“MOST”) has targeted stem cell development as high
priority field, and development in this field has been intense in
the agencies under MOST. For example, the 973 Program has funded a
number of stem cell research projects such as differentiation of
human embryonic germ cells and the plasticity of adult stem cells.
Notwithstanding such government support, China has had a highly
fragmented cellular medicine landscape. Shenzhen Beike
Biotechnology Co. Ltd. (“Beike”) and Union Stem Cell
& Gene Engineering Co., Ltd. (“Union Stem Cell”)
are two large stem cell companies in China. To the best of our
knowledge, none of the Chinese companies are utilizing our proposed
international manufacturing protocol and our unique technologies in
conducting what we believe will be fully compliant CFDA-sanctioned
clinical trials to commercialize cell therapies in China. Our
management believes that it is difficult for most of these Chinese
companies to turn their results into translational stem cell
science or commercially successful therapeutic products using
internationally acceptable standards.
We compete globally
with respect to the discovery and development of new cell based
therapies, and we also compete within China to bring new therapies
to market. The biotechnology industry, namely in the areas of cell
processing and manufacturing, clinical development of cellular
therapies and cell collection, processing and storage, are
characterized by rapidly evolving technology and intense
competition. Our competitors worldwide include pharmaceutical,
biopharmaceutical and biotechnology companies, as well as numerous
academic and research institutions and government agencies engaged
in drug discovery activities or funding, in the U.S., Europe and
Asia. Many of these companies are well-established and possess
technical, research and development, financial, and sales and
marketing resources significantly greater than ours. In addition,
many of our smaller potential competitors have formed strategic
collaborations, partnerships and other types of joint ventures with
larger, well established industry competitors that afford these
companies potential research and development and commercialization
advantages in the technology and therapeutic areas currently being
pursued by us. Academic institutions, governmental agencies and
other public and private research organizations are also conducting
and financing research activities which may produce products
directly competitive to those being commercialized by us. Moreover,
many of these competitors may be able to obtain patent protection,
obtain government (e.g. FDA) and other regulatory approvals and
begin commercial sales of their products before us.
Our primary
competitors in the field of stem cell therapy for osteoarthritis,
and other indications include Beike, Cytori Therapeutics
Inc.(“Cytori”), Caladrius Biosciences, Inc. and others.
Among our competitors, to our knowledge, the only ones based in and
operating in Greater China are Beike, Lorem Vascular and Olife Bio.
Lorem Vascular has partnered with Cytori to commercialize Cytori
Cell Therapy for the cardiovascular, renal and diabetes markets in
China and Hong Kong. Olife Bio, a Medi-Post joint venture with
JingYuan Bio in Taian, Shandong Province, plans to initiate
clinical trial in China in 2016. Our primary competitors in the
field of cancer immune cell therapies include pharmaceutical,
biotechnology companies such as Northwest Biotherapeutics, Inc.,
Juno Therapeutics, Inc., Kite Pharma, Inc., CARSgen, Sorrento
Therapeutics, Inc. and others. Among our competitors, the ones
based in and operating in Greater China are BeiGene, Limited,
CARsgen and China Oncology Focus Limited, which has licensed
Sorrento’s anti-PD-L1 monoclonal antibody for Greater China.
Other western big pharma and biotech companies in the cancer immune
cell therapies space are starting to make inroads into China by
partnering or seeking to partner with local companies. For example,
in April, 2016, Seattle-based Juno Therapeutics, Inc. started a new
company with WuXi AppTec in China named JW Biotechnology (Shanghai)
Co., Ltd. Its mission is to build China's leading cell therapy
company by leveraging Juno's chimeric antigen receptor (CAR) and T
cell receptor (TCR) technologies together with WuXi AppTec's
R&D and manufacturing platform and local expertise to develop
novel cell-based immunotherapies for patients with hematologic and
solid organ cancers. In January 2017, Shanghai Fosun Pharmaceutical
created a joint venture with Santa Monica-based Kite Pharma Inc. to
develop, manufacture and commercialize axicabtagene ciloleucel in
China with the option to include additional products, including two
T cell receptor (TCR) product candidates from Kite. Axicabtagene
ciloleucel is Kite's lead product candidate and is an
investigational chimeric antigen receptor (CAR) T-cell therapy
under development for the treatment of B-cell lymphomas and
leukemias. In late 2017 Gilead acquired Kite Pharma for $11.9
billion. On January 22, 2018 Celgene announced that it had agreed
to buy Juno Therapeutics for approximately $9 billion.
The CFDA has
received six applications for CD19 chimeric antigen receptor T
cells cancer therapies from different companies. The applicants are
Nanjing Legend biotechnology, Chengdu Yinhe Biological Medicine,
Shanghai HRAIN Biotechnology, Carsgene Biomedicine (Shanghai),
Biogene ANKE Cell Technology and Shanghai Mingju
Biotechnology.
Additionally, in
the general area of cell-based therapies for knee osteoarthritis
ailments, we potentially compete with a variety of companies, from
large pharmaceutical companies to specialty medical products or
biotechnology companies. Some of these, such as Abbvie, Merck KGaA,
Sanofi, Teva, GlaxosmithKline, Baxter, Johnson & Johnson,
Medtronic and Miltenyi Biotec, are well-established and have
substantial technical and financial resources compared to ours.
However, as cell-based products are only just emerging as viable
medical therapies, many of our more direct competitors are smaller
biotechnology and specialty medical products companies. These
include Vericel Corporation, Regeneus Ltd., Advanced Cell
Technology, Inc., Nuo Therapeutics, Inc., Arteriocyte Medical
Systems, Inc., Athersys, Inc., Bioheart, Inc., Cytori, Harvest
Technologies Corporation, Mesoblast, Pluristem, Inc., TissueGene,
Inc., Medipost Co., Ltd. and others. There are also several non
cell-based, small molecule and peptide clinical trials targeting
knee osteoarthritis and several other FDA approved treatment for
knee pain.
Some of our
competitors also work with adipose-derived stem cells. To our
knowledge, none of these companies are currently utilizing the same
technologies as ours to treat KOA, nor to our knowledge are any of
these companies conducting government-approved clinical trials in
China.
We believe we have
a strategic advantage over our competitors based on our ability to
meet cGMP regulatory requirements, a capability which we believe is
possessed by few to none of our competitors in China, in an
industry in which meeting exacting standards and achieving
extremely high purity levels is crucial to success. In addition, in
comparison to the broader range of cellar biopharmaceutical firms,
we believe we have the advantages of cost and expediency, and a
first mover advantage with respect to commercialization of cell
therapy products and treatments in the Greater China
market.
Corporate Structure, Subsidiaries and Affiliates
Our current
corporate structure is illustrated in the following
diagram:
We conduct our
business operations through the following subsidiaries (including a
controlled various interest entity
(“VIE”):
Cellular
Biomedicine Group HK Limited is a Hong Kong company limited by
shares, a holding company and wholly owned subsidiary of the
Company.
Cellular
Biomedicine Group Ltd. (Wuxi), license number 320200400034410 (the
“WFOE”), is a wholly foreign-owned entity that is 100%
owned by Cellular Biomedicine Group HK Limited. This entity’s
legal name in China translates to “Xi Biman Biological
Technology (Wuxi) Co. Ltd.” WFOE controls and holds ownership
rights in the business, assets and operations of Cellular
Biomedicine Group Ltd. (Shanghai) (“CBMG Shanghai”)
through variable interest entity (VIE) agreements. We conduct
certain biopharmaceutical business activities through WFOE,
including lab kit production and research.
Cellular
Biomedicine Group Ltd. (Shanghai) license number 310104000501869
(“CBMG Shanghai”), is a PRC domestic corporation, which
we control and hold ownership rights in, through WFOE and the
above-mentioned VIE agreements. This entity’s legal name in
China translates to “Xi Biman Biotech (Shanghai) Co.,
Ltd.” We conduct certain biopharmaceutical business
activities through our controlled VIE entity and CBMG Shanghai,
including clinical trials and certain other activities requiring a
domestic license in the PRC. Mr. Chen Mingzhe and Mr. Lu Junfeng
together are the record holders of all of the outstanding
registered capital of CBMG Shanghai. Mr. Chen and Mr. Lu are also
directors of CBMG Shanghai constituting the entire management of
the same. Mr. Chen and Mr. Lu receive no compensation for their
roles as managers of CBMG Shanghai.
Beijing Agreen
Biotechnology Co., Ltd. (“AG”) is a PRC domestic
corporation and a wholly owned subsidiary of CBMG
Shanghai.
Wuxi Cellular
Biopharmaceutical Group Ltd. is a PRC domestic corporation and a
wholly owned subsidiary of CBMG Shanghai.
Shanghai Cellular
Biopharmaceutical Group Ltd. was established on January 18, 2017.
It is a PRC domestic corporation and wholly owned subsidiary of
CBMG Shanghai.
Eastbridge
Investment Corporation, a Delaware corporation, is a wholly owned
subsidiary of the Company.
Cellular
Biomedicine Group VAX, Inc., a California corporation, is a wholly
owned subsidiary of the Company.
Additional
Information
Since inception and
through December 31, 2017, we have recorded accumulated losses
totaling approximately $111 million. Our historical operating
losses have resulted principally from our research and development
activities, including clinical trial activities for our product
candidates and general and administrative expenses. Ultimately, if
we secure additional approvals from the MOH, CFDA and other
regulatory bodies throughout the world for our product candidates,
our goal will be to augment our current sources of revenue and, as
applicable, deferred revenue (principally licensing fees), with
sales of such products or royalties from such sales, on which we
may pay royalties or other fees to our licensors and/or third-party
collaborators as applicable.
We have based our
estimates of development costs, market size estimates, peak annual
sales projections and similar matters described or incorporated by
reference in this prospectus on our market research, third party
reports and publicly available information which we consider
reliable. However, readers are advised that the projected dates for
filing and approval of our drug applications with the MOH, CFDA or
other regulatory authorities, our estimates of development costs,
our projected sales and similar metrics regarding our
KOA and CD therapies or any other product
candidates discussed elsewhere (or incorporated by reference) in
this prospectus are merely estimates and subject to many factors,
many of which may be beyond our control, which will likely cause us
to revise such estimates. Readers are also advised that our
projected sales figures do not take into account the royalties and
other payments we will need to make to our licensors and strategic
partners. Our estimates are based upon our management’s
reasonable judgments given the information available and their
previous experiences, although such estimates may not prove to be
accurate.
Corporate
Information
Our principal
executive offices are located at 19925 Stevens Creek Blvd., Suite
100 Cupertino, CA 95014. Our telephone number is: (408)
973-7884.
The
Offering
Common
stock outstanding prior to the offering
|
17,453,623 and
16,991,367 shares of common stock issued and outstanding as of
March 28, 2018.
|
Common
stock offered by the Selling Stockholders
|
Up to 2,927,658
shares of common stock for sale by the Selling Stockholders for
their own account. These shares include:
(i) Up to 41,667
shares of our common stock issued in connection with the Management
Tranche;
(ii) up to
1,166,667 shares of our common stock issued in connection with the
Investor Tranche;
(iii) up to
1,719,324 shares of our common stock issued in connection with the
February PIPE.
|
Proceeds
|
We will not receive
any proceeds from the sale of our common stock by the Selling
Stockholders.
|
Risk
Factors
|
The securities
offered hereby involve a high degree of risk. See “Risk
Factors.”
|
NASDAQ
Global Market Symbol
|
CBMG
|
The number of
shares of our common stock that will be outstanding immediately
prior this offering as shown above is based on 17,453,623 shares
outstanding as of March 28, 2018. The number of shares outstanding
as of the date of this prospectus, as used throughout this
prospectus, unless otherwise indicated, excludes the following, all
as of March 28, 2018:
●
273,847
shares of our common stock issuable upon exercise of stock options
outstanding under our 2011 Incentive Stock Option Plan, which had a
weighted average exercise price of $5.77 per share;
●
648,378
shares of our common stock issuable upon exercise of stock options
outstanding under our 2013 Stock Incentive Plan, which had a
weighted average exercise price of $ 9.19 per share;
and
●
891,727
shares of our common stock issuable upon exercise of stock options
outstanding under our 2014 Stock Incentive Plan, which had a
weighted average exercise price of $15.74 per share, and 856,481
shares of our common stock outstanding under our 2014 Stock
Incentive Plan subject to vest before March 27, 2022.
RISK
FACTORS
We have included
discussions of the risks, uncertainties and assumptions under the
heading “Risk Factors” included in our Annual Report on
Form 10-K for the year ended December 31, 2017, which risk factors
are incorporated by reference into this prospectus. See
“Where You Can Find More Information” for an
explanation of how to get a copy of this report. Additional risks
related to our securities may also be described in a prospectus
supplement and in any related free writing prospectus that we may
authorize to be provided to you.
Investing in our securities involves a high
degree of risk. Before deciding whether to invest in our
securities, you should carefully consider the risk factors we
describe in any prospectus supplement and in any related free
writing prospectus that we may authorize to be provided to you or
in any report incorporated by reference into this prospectus or
such prospectus supplement, including our Annual Report on Form
10-K for the year ended December 31, 2017, or any Annual Report on
Form 10-K or Quarterly Report on Form 10-Q that is incorporated by
reference into this prospectus or such prospectus supplement after
the date of this prospectus. Although we discuss key risks in those
risk factor descriptions, additional risks not currently known to
us or that we currently deem immaterial also may impair our
business. Our subsequent filings with the SEC may contain amended
and updated discussions of significant risks. We cannot predict
future risks or estimate the extent to which they may affect our
financial performance.
Please also read
carefully the section above entitled “Cautionary Note
Regarding Forward-Looking Statements.”
USE
OF PROCEEDS
We will not receive
any proceeds from the sale of shares registered hereunder by the
selling stockholders.
DETERMINATION
OF OFFERING PRICE
The
selling stockholders will offer common stock at the prevailing
market prices or privately negotiated price as they may determine
from time to time.
The
offering price of our common stock to be sold by the selling
stockholders does not necessarily bear any relationship to our book
value, assets, past operating results, financial condition or any
other established criteria of value. The facts considered in
determining the offering price were our financial condition and
prospects, our limited operating history and the general condition
of the securities market.
In
addition, there is no assurance that our common stock will trade at
market prices in excess of the offering price as prices for common
stock in any public market will be determined in the marketplace
and may be influenced by many factors, including the depth and
liquidity.
SELLING STOCKHOLDERS
The
following table sets forth certain information as of March 28, 2018
regarding the selling stockholders and the shares offered by them
in this prospectus. In computing the number of shares owned by a
person and the percentage ownership of that person in the table
below, securities that are currently convertible or exercisable
into shares of our common stock that are being offered in this
prospectus are deemed outstanding. Such shares, however, are not
deemed outstanding for the purposes of computing the percentage
ownership of any other person. Except as indicated in the footnotes
to the following table, each stockholder named in the table has
sole voting and investment power with respect to the shares set
forth opposite such stockholder’s name. The percentage of
ownership of each selling stockholder in the following table is
based upon 17,453,623 shares of common stock issued as of March 28,
2018 plus shares the selling stockholders will receive upon
exercise of warrants or conversion of debt which are being offered
in this offering.
Except
as set forth below, no selling stockholder has held a position as
an officer or director of the Company, nor has any material
relationship of any kind with us or any of our affiliates. All
information with respect to share ownership has been furnished by
the selling stockholders. The common stock being offered is being
registered to permit secondary trading of the shares and the
selling stockholders may offer all or part of the common stock
owned for resale from time to time. Except as set forth below, none
of the selling stockholders have any family relationships with our
officers, directors or controlling stockholders. Furthermore, none
of the selling stockholders are a registered broker-dealer or an
affiliate of a registered broker-dealer.
The
term “selling stockholder” also includes any
transferees, pledges, donees, or other successors in interest to
the selling stockholder named in the table below. To our knowledge,
subject to applicable community property laws, each person named in
the table has sole voting and investment power with respect to the
common stock set forth opposite such person’s name. We will
file a supplement to this prospectus (or a post-effective amendment
hereto, if necessary) to name successors to any named selling
stockholder who is able to use this prospectus to resell the
securities registered hereby.
* Less than
1%
(1)
James
Xiao Dong Liu is the sole director of Wealth Map Holdings Limited.
The investment committee of Sailing Capital Overseas Investments
Fund, L.P. has decision making power over voting and disposition of
the CBMG securities owned by Wealth Map Holdings
Limited.
(2)
James
Xiao Dong Liu, as the sole director of Earls Mill Limited, has
voting and dispositive power over the CBMG securities owned by
Earls Mill Limited.
(3)
RTSing
Raffles Limited and RTSing Marina Limited, as the MapleBrook
Limited’s corporate directors, can act jointly to dispose of
and vote on the securities in accordance with the Memorandum of
Association of MapleBrook Limited. Britta Pfister, Patricia Tan and
Chue Chee Chen, individual directors of both RTSing Raffles Limited
and RTSing Marina Limited, have voting and dispositive power over
the shares owned by MapleBrook Limited.
(4)
Bizuo
(Tony) Liu’s total number of shares owned prior to the
offering and after the offering include 35,300 options issued under
the 2011 Plan, 255,000 options issued under 2013 Plan and 325,800
options issued under 2014 Plan, of which an aggregate of 500,600
are currently vested and exercisable as of March 28,
2018.
(5)
Andrew
Chan’s total number of shares owned prior to the offering and
after the offering include 53,880 options issued under the 2011
Plan, 37,904 options issued under 2013 Plan and 38,000 options
issued under 2014 Plan, of which an aggregate of 107,011 are
currently vested and exercisable as of March 28, 2018.
(6)
Yihong
Yao’s total number of shares owned prior to the offering and
after the offering include 61,500 options issued under 2014 Plan,
of which an aggregate of 25,176 are currently vested and
exercisable as of March 28, 2018.
(7)
Ming Li, as a director of Winsor
Capital Limited, has voting and dispositive power over the CBMG
securities owned by Winsor Capital Limited .
PLAN
OF DISTRIBUTION
Selling Stockholders
The
common stock held by the selling stockholders may be sold or
distributed from time to time by the selling stockholders directly
to one or more purchasers or through brokers, dealers, or
underwriters who may act solely as agents at market prices
prevailing at the time of sale, at prices related to the prevailing
market prices, at negotiated prices, or at fixed prices, which may
be changed on any stock exchange, market or trading facility on
which the shares are traded or in private transactions. The sale of
the selling stockholders’ common stock offered by this
prospectus may be effected in one or more of the following
methods:
●
ordinary
brokerage transactions and transactions in which the broker-dealer
solicits purchasers;
●
transactions
involving cross or block trades;
●
purchases
by a broker-dealer as principal and resale by the broker-dealer for
its account;
●
an
exchange distribution in accordance with the rules of the
applicable exchange;
●
in
privately negotiated transactions;
●
short
sales after the registration statement, of which this prospectus
forms a part, becomes effective;
●
broker-dealers
may agree with the selling stockholders to sell a specified number
of such shares at a stipulated price per share;
●
“at
the market” into an existing market for the common
stock;
●
through
the writing of options on the shares;
●
a
combination of any such methods of sale; and
●
any
other method permitted pursuant to applicable law.
In
order to comply with the securities laws of certain states, if
applicable, the shares of each of the selling stockholders may be
sold only through registered or licensed brokers or dealers. In
addition, in certain states, such shares may not be sold unless
they have been registered or qualified for sale in the state or an
exemption from the registration or qualification requirement is
available and complied with.
The
selling stockholders may also sell shares of common stock under
Rule 144 promulgated under the Securities Act, if available, rather
than under this prospectus. In addition, the selling stockholders
may transfer the shares of common stock by other means not
described in this prospectus.
The
selling stockholders may also sell the shares directly to market
makers acting as principals and/or broker-dealers acting as agents
for themselves or their customers. Such broker-dealers may receive
compensation in the form of discounts, concessions or commissions
from the selling stockholders and/or the purchasers of shares for
whom such broker-dealers may act as agents or to whom they sell as
principal or both, which compensation as to a particular
broker-dealer might be in excess of customary commissions. Market
makers and block purchasers purchasing the shares will do so for
their own account and at their own risk. It is possible that a
selling stockholder will attempt to sell shares of common stock in
block transactions to market makers or other purchasers at a price
per share which may be below the then market price. The selling
stockholders cannot assure that all or any of the shares offered in
this prospectus will be issued to, or sold by, such selling
stockholder.
Brokers,
dealers, underwriters, or agents participating in the distribution
of the shares held by the selling stockholders as agents may
receive compensation in the form of commissions, discounts, or
concessions from the selling stockholders and/or purchasers of the
common stock for whom the broker-dealers may act as agent. The
selling stockholders may agree to indemnify any agent, dealer or
broker-dealer that participates in transactions involving sales of
the shares if liabilities are imposed on that person under the
Securities Act.
Each
of the selling stockholders acquired the securities offered hereby
in the ordinary course of business and has advised us that they
have not entered into any agreements, understandings or
arrangements with any underwriters or broker-dealers regarding the
sale of their shares of common stock, nor is there an underwriter
or coordinating broker acting in connection with a proposed sale of
shares of common stock by any selling stockholder. If we are
notified by any selling stockholder that any material arrangement
has been entered into with a broker-dealer for the sale of shares
of common stock, if required, we will file a supplement to this
prospectus.
With
regard only to the shares it sells for its own behalf, each selling
stockholder may be deemed an “underwriter” within the
meaning of the Securities Act. This offering as it relates to each
selling stockholder will terminate on the date that all shares
issued to and issuable to such selling stockholder that are offered
by this prospectus have been sold by such selling
stockholder.
We
may suspend the sale of shares by the selling stockholders pursuant
to this prospectus for certain periods of time for certain reasons,
including if the prospectus is required to be supplemented or
amended to include additional material information.
If
any of the selling stockholders use this prospectus for any sale of
the shares of common stock, such selling stockholder will be
subject to the prospectus delivery requirements of the Securities
Act.
Regulation M
The
anti-manipulation rules of Regulation M under the Exchange Act of
1934, as amended (the “Exchange Act”) may apply to
sales of our common stock and activities of the selling
stockholder.
We
have advised the selling stockholders that while it is engaged in a
distribution of the shares included in this prospectus it is
required to comply with Regulation M promulgated under the Exchange
Act. With certain exceptions, Regulation M precludes the selling
stockholder, any affiliated purchasers, and any broker-dealer or
other person who participates in the distribution from bidding for
or purchasing, or attempting to induce any person to bid for or
purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also
prohibits any bids or purchases made in order to stabilize the
price of a security in connection with the distribution of that
security. All of the foregoing may affect the marketability of the
shares offered hereby this prospectus.
DESCRIPTION OF SECURITIES TO BE REGISTERED
General
Our authorized
capital stock consists of 300,000,000 shares of common stock and
50,000,000 shares of preferred stock. As of the date of this
prospectus, our outstanding capital stock consists of 17,453,623
shares of common stock, $0.001 par value, and no shares of
preferred stock. These figures do not include securities that may
be issued: (i) pursuant to our Amended and Restated 2011 Incentive
Plan; (ii) pursuant to our 2013 Stock Incentive Plan; or (iii)
pursuant to our 2014 Stock Incentive Plan, as amended.
We are a Delaware
corporation and our affairs are governed by our Certificate of
Incorporation and By-laws. The following are summaries of material
provisions of our Certificate of Incorporation and By-laws insofar
as they relate to the material terms of our common shares. Complete
copies of our Certificate of Incorporation and By-laws are filed as
exhibits to our public filings.
Common
Stock
Our
common stock is listed on the Nasdaq Global Market under the symbol
“CBMG.”
All outstanding shares of common stock are of the
same class and have equal rights and attributes. The holders of
common stock are entitled to one vote per share on all matters
submitted to a vote of stockholders of the Company. All
stockholders are entitled to share equally in dividends, if any, as
may be declared from time to time by the Board of Directors out of
funds legally available. In the event of liquidation, the holders
of common stock are entitled to share ratably in all assets
remaining after payment of all liabilities. The stockholders do not
have cumulative or preemptive rights.
Dividend
Rights
Holders
of the common stock may receive dividends when, as and if declared
by our Board of Directors out of the assets legally available for
that purpose and subject to the preferential dividend rights of any
other classes or series of stock of our Company. We have never
paid, and have no plans to pay, any dividends on our shares of
common stock.
Voting
Rights
Holders
of the common stock are entitled to one vote per share in all
matters as to which holders of common stock are entitled to vote.
Holders of not less than a majority of the outstanding shares of
common stock entitled to vote at any meeting of stockholders
constitute a quorum unless otherwise required by law.
Election of Directors
Directors
hold office until the next annual meeting of stockholders and are
eligible for reelection at such meeting. Directors are elected by a
plurality of the shares present in person or represented by proxy
at the meeting and entitled to vote on the election of directors.
There is no cumulative voting for directors.
Liquidation
In
the event of any liquidation, dissolution or winding up of the
Company, holders of the common stock have the right to receive
ratably and equally all of the assets remaining after payment of
liabilities and liquidation preferences of any preferred stock then
outstanding.
Redemption
The
common stock is not redeemable or convertible and does not have any
sinking fund provisions.
Preemptive Rights
Holders
of the common stock do not have preemptive rights.
Other Rights
Our
common stock is not liable to calls or to assessment or for
liabilities imposed on our stockholders under state
statutes.
Our board is
divided into three classes, each of which will generally serve for
a term of three years with only one class of directors being
elected in each year. The common stock has no cumulative voting
rights, including with respect to the election of
directors.
LEGAL
MATTERS
The validity of the
securities offered by this prospectus, and any supplement thereto,
will be passed upon for us by Ellenoff Grossman & Schole LLP,
New York, NY.
EXPERTS
The financial
statements for the years ended December 31, 2017, 2016 and 2015
incorporated in this prospectus by reference to the Annual Report
on Form 10-K for the year ended December 31, 2017 has been so
incorporated in reliance on the report of BDO China Shu Lun Pan
Certified Public Accountants LLP, an independent registered public
accounting firm, given on the authority of such firm as an expert
in auditing and accounting.
WHERE
YOU CAN FIND MORE INFORMATION
We have filed a
registration statement with the Securities and Exchange Commission
under the Securities Act with respect to the shares of our common
stock offered by this prospectus. This prospectus is part of that
registration statement and does not contain all the information
included in the registration statement.
For further
information with respect to our common stock and us, you should
refer to the registration statement, its exhibits and the material
incorporated by reference therein. Portions of the exhibits have
been omitted as permitted by the rules and regulations of the
Securities and Exchange Commission. Statements made in this
prospectus as to the contents of any contract, agreement or other
document referred to are not necessarily complete. In each
instance, we refer you to the copy of the contracts or other
documents filed as an exhibit to the registration statement, and
these statements are hereby qualified in their entirety by
reference to the contract or document. The registration statement
may be inspected and copied at the public reference facilities
maintained by the Securities and Exchange Commission at Room 1024,
Judiciary Plaza, 100 F Street, N.E., Washington, D.C. 20549 and the
Regional Offices at the Commission located in the Citicorp Center,
500 West Madison Street, Suite 1400, Chicago, Illinois 60661, and
at 233 Broadway, New York, NY 10279. Copies of those filings can be
obtained from the Commission’s Public Reference Section,
Judiciary Plaza, 100 F Fifth Street, N.E., Washington, D.C. 20549
at prescribed rates and may also be obtained from the web site that
the Securities and Exchange Commission maintains at
http://www.sec.gov. You may also call the Commission at
1-800-SEC-0330 for more information. We file annual, quarterly and
current reports and other information with the Securities and
Exchange Commission. You may read and copy any reports, statements
or other information on file at the Commission’s public
reference room in Washington, D.C. You can request copies of those
documents upon payment of a duplicating fee, by writing to the
Securities and Exchange Commission.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
We are
“incorporating by reference” certain documents we file
with the SEC, which means that we can disclose important
information to you by referring you to those documents. The
information in the documents incorporated by reference is
considered to be part of this prospectus. Statements contained in
documents that we file with the SEC and that are incorporated by
reference in this prospectus will automatically update and
supersede information contained in this prospectus supplement,
including information in previously filed documents or reports that
have been incorporated by reference in this prospectus, to the
extent the new information differs from or is inconsistent with the
old information. We have filed or may file the following documents
with the SEC and they are incorporated herein by reference as of
their respective dates of filing:
●
our Annual Report on Form 10-K for the year ended
December 31, 2017 as filed with the SEC on March 5,
2018;
●
our
Current Reports on Form 8-K and/or their amendments as filed with
the SEC on January 31, 2018, February 7, 2018 , February 12, 2018
and February 15, 2018;
●
the
information specifically incorporated by reference into our Annual
Report on Form 10-K for the year ended December 31, 2017 from our
definitive proxy statement on Schedule 14A related to our 2018
annual meeting of stockholders, which was filed with the SEC on
March 12, 2018;
●
the
description of our Common Stock contained in our Form 8-A filed
with the SEC on June 13, 2014, and as it may be further amended
from time to time, under the caption “Item 1. Description of
Registrant’s Securities to be Registered.”
All reports and
definitive proxy or information statements filed pursuant to
Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to
the filing of this Registration Statement and prior to the filing
of a post-effective amendment which indicates that all securities
offered hereby have been sold or which de-registers all securities
then remaining unsold shall be deemed to be incorporated by
reference into this Registration Statement and to be a part hereof
from the date of filing such documents, except as to specific
sections of such statements as set forth therein. Any statement
contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a
statement contained in any subsequently filed document which also
is deemed to be incorporated by reference herein modifies or
supersedes such statement.
You may request a
copy of these filings at no cost (other than exhibits unless such
exhibits are specifically incorporated by reference) by writing or
telephoning us at the following address and telephone
number:
Cellular
Biomedicine Group, Inc.
19925 Stevens Creek
Blvd., Suite 100
Cupertino, CA
95014
Telephone: (408)
973-7884
Attention: Tony
Liu
DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION FOR SECURITIES LAW VIOLATIONS
Our
directors and officers are indemnified to the fullest extent
permitted under Delaware law. We may also purchase and maintain
insurance which protects our officers and directors against any
liabilities incurred in connection with their service in such a
capacity, and such a policy may be obtained by us in the
future.
Insofar
as indemnification for liabilities arising under the Securities Act
may be permitted to our directors, officers and controlling persons
pursuant to the foregoing, or otherwise, we have been advised that
in the opinion of the SEC such indemnification is against public
policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by us of expenses
incurred or paid by a director, officer or controlling person of
ours in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in
connection with the securities being registered, we will, unless in
the opinion of our counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.
You should rely only on the information contained in this document.
We have not authorized anyone to provide you with information that
is different. This document may only be used where it is legal to
sell these securities. The information in this document may only be
accurate on the date of this document.
Additional risks and uncertainties not presently known or that are
currently deemed immaterial may also impair our business
operations. The risks and uncertainties described in this document
and other risks and uncertainties which we may face in the future
will have a greater impact on those who purchase our common stock.
These purchasers will purchase our common stock at the market price
or at a privately negotiated price and will run the risk of losing
their entire investment.
Up
to 2,927,658 Shares of
Common
Stock
Prospectus
April
11, 2018
You
should rely only on the information contained in this prospectus.
We have not authorized anyone to provide you with information
different from that contained in this prospectus or any prospectus
supplement. This prospectus is not an offer of these securities in
any jurisdiction where an offer and sale is not permitted. The
information contained in this prospectus is accurate only as of the
date of this prospectus, regardless of the time of delivery of this
prospectus or any sale of our common stock.